Scott Rocklage has had a varied professional life in healthcare management, business and the life sciences for over 20 years. Mr. Rocklage says no two days follow a typical schedule. He credits his effectiveness to being well-organized in terms of time management, calendaring and prioritizing matters of importance.
Scott Rocklage received his B.S. degree in Chemistry from the University of California, Berkley. His Ph.D is from the Massachusetts Institute of Technology in Chemistry. In 2003, Mr. Rocklage became a venture partner with 5AM Ventures, and was promoted to managing partner one year later.
The company, 5AM Ventures, is a life sciences-based company. It works with other entities that are in early development or formation, and, that in part is the reason for the name of the company, 5AM Ventures.
Scott Rocklage has an active involvement in healthcare management outside 5AM Ventures. He has served in executive capacity with Nycomed Salutar and Nycomed Interventional. Moreover, he has held board of director memberships with the Whitehead Institute, Achaogen and Semprus. Presently, he works out of the Boston, Massachusetts office of 5AM Ventures. Mr. Rocklage has several patents as inventor or co-inventor, has been featured in 100 peer-reviewed publications, and was instrumental in leading the way toward FDA approval of three treatment protocols. These are Omniscan, Cubicin, and Teslascan. Mr. Rocklage has a high degree of interest in the steady growth to target mutations that will result in new forms of cancer treatment. He enjoys helping entrepreneurs, physicians and scientists shape their ideas into real possibilities that could find application in the marketplace. Learn more: http://5amventures.com/team/scott-m-rocklage-phd/